Cerevel Therapeutics Holdings, Inc.

Cerevel Therapeutics Holdings, Inc.verified

CERE

Price:

$41.33

Market Cap:

$7.53B

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-concept trial in patients with drug-resistant focal onset seizures in epilepsy or focal epilepsy, as well as in phase 1 trial to treat acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in phase 3 clinical trial for the treatment of early- and late-stage Parkinson's disease; CVL-871, a sel...[Read more]

Industry

Biotechnology

IPO Date

2020-07-30

Stock Exchange

NASDAQ

Ticker

CERE

The PE Ratio as of May 2024 (TTM) for Cerevel Therapeutics Holdings, Inc. (CERE) is -15.14

According to Cerevel Therapeutics Holdings, Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -15.14. This represents a change of 21.17% compared to the average of -12.49 of the last 4 quarters.

Cerevel Therapeutics Holdings, Inc. (CERE) Historical PE Ratio (quarterly & annually)

How has CERE PE Ratio performed in the past?

The mean historical PE Ratio of Cerevel Therapeutics Holdings, Inc. over the last ten years is -9.20. The current -15.14 PE Ratio has changed 16.36% with respect to the historical average. Over the past ten years (40 quarters), CERE's PE Ratio was at its highest in in the February 2012 quarter at 24.91. The PE Ratio was at its lowest in in the February 2001 quarter at -7123.71.

Quarterly (TTM)
Annual

Average

-9.20

Median

-7.02

Minimum

-19.91

Maximum

-0.07

Cerevel Therapeutics Holdings, Inc. (CERE) PE Ratio by Quarter and Year

Discovering the peaks and valleys of Cerevel Therapeutics Holdings, Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Maximum Annual Increase = 16.23%

Maximum Annual PE Ratio = -0.07

Minimum Annual Increase = -Infinity%

Minimum Annual PE Ratio = -19.91

Quarterly (TTM)
Annual
YearPE RatioChange
2023-15.8716.96%
2022-13.57-31.81%
2021-19.91148.03%
2020-8.03-31.89%
2019-11.7816.23%
2018-0.07-98.80%
2015-6.024.14%
2014-5.7810.88%
2013-5.21-9.54%
2012-5.76-Infinity%

Cerevel Therapeutics Holdings, Inc. (CERE) Average PE Ratio

How has CERE PE Ratio performed in the past?

The current PE Ratio of Cerevel Therapeutics Holdings, Inc. (CERE) is greater than its 3-year, less than than its 5-year, and less than than its 10-year historical averages

3-year avg

-16.45

5-year avg

-13.83

10-year avg

-9.20

Cerevel Therapeutics Holdings, Inc. (CERE) PE Ratio vs. Peers

How is CERE’s PE Ratio compared to its peers?

Cerevel Therapeutics Holdings, Inc.’s PE Ratio is less than Avidity Biosciences, Inc. (-10.47), less than Revolution Medicines, Inc. (-12.91), less than Day One Biopharmaceuticals, Inc. (-5.71), less than SpringWorks Therapeutics, Inc. (-9.22), less than Ventyx Biosciences, Inc. (-1.40), greater than Nuvalent, Inc. (-29.96), less than Travere Therapeutics, Inc. (-2.95), greater than Structure Therapeutics Inc. (-17.64), less than Monte Rosa Therapeutics, Inc. (-1.85), less than Design Therapeutics, Inc. (-4.20), less than Werewolf Therapeutics, Inc. (-4.88), less than Ikena Oncology, Inc. (-0.92), less than Stoke Therapeutics, Inc. (-6.14), less than Apellis Pharmaceuticals, Inc. (-11.97), less than Terns Pharmaceuticals, Inc. (-4.90), greater than Blueprint Medicines Corporation (-21.96), less than IGM Biosciences, Inc. (-2.42), less than Cullinan Oncology, Inc. (-7.84), less than Mineralys Therapeutics, Inc. (-6.03),

Build a custom stock screener for Cerevel Therapeutics Holdings, Inc. (CERE) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cerevel Therapeutics Holdings, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Custom stock screener in Wisesheets

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Cerevel Therapeutics Holdings, Inc. (CERE) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Cerevel Therapeutics Holdings, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Custom stock templates in Wisesheets

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.

Frequently asked questions❓

What is the PE Ratio?

How can you use the PE Ratio?

What is Cerevel Therapeutics Holdings, Inc.'s PE Ratio?

How is the PE Ratio calculated for Cerevel Therapeutics Holdings, Inc. (CERE)?

What is the highest PE Ratio for Cerevel Therapeutics Holdings, Inc. (CERE)?

What is the 3-year average PE Ratio for Cerevel Therapeutics Holdings, Inc. (CERE)?

What is the 5-year average PE Ratio for Cerevel Therapeutics Holdings, Inc. (CERE)?

How does the current PE Ratio for Cerevel Therapeutics Holdings, Inc. (CERE) compare to its historical average?